Clinical Translation

The biomedical industry has proven that new molecular targets can open entirely new market opportunities. Immuno-oncology went from fringe to first-line therapy.[1] Gene editing moved from theory to FDA approval with Casgevy.[2] Yet biotech has had insufficient incentives for pre-disease therapeutics. Blood cholesterol, identified as early as the 1950s, was a rare prevention breakthrough that took decades to translate into widely-accessible statins.[3]

With so few biomarkers and interventions to prevent disease, consumers have sought alternatives. The wellness industry has surged past $5 trillion,[4] largely filling a vacuum that evidence-based prevention should occupy. The gap between environmental exposure science and clinical medicine remains vast. Millions of chemicals have been tested for toxicity, but almost none have yielded FDA-approved interventions targeting their biological effects.

Pharma has opened a new window by successfully intervening on interrelated body systems at earlier stages of pre-disease. GLP-1 receptor agonists, originally developed for type 2 diabetes, now show cardiovascular, renal, hepatic, and neurological effects due to diffuse receptor distribution.[5] The models developed for studying multi-system-level circuitry for endocrine-signaling drug classes could be transferred to environmental health.

The parallels are striking: neurodegenerative diseases (NDs) like Parkinson's and Alzheimer's involve multi-organ dysfunction with environmental exposure as a significant risk factor.[6] Pesticides such as rotenone and paraquat have been epidemiologically linked to Parkinson's disease,[7] while air pollution accelerates cognitive decline in Alzheimer's.[8] Finding the common denominators of environmental chemical exposure across NDs is the same multi-tissue, multi-receptor challenge that GLP-1 research navigated.

Clinical models already exist to study these connections. The gut-brain axis, disrupted by both pesticides and metabolic dysfunction, is a shared pathway between environmental exposures and NDs.[9] Researchers studying GLP-1's neuroprotective effects in Parkinson's[10] have built infrastructure that could be repurposed to test interventions against exposure-driven neurodegeneration.

New mechanisms from environmental exposure research yield positive externalities for clinical science. The aryl hydrocarbon receptor (AhR), discovered through dioxin toxicology, became a validated drug target. Tapinarof is now FDA-approved for psoriasis,[11] with 20+ clinical trials exploring AhR modulators for chronic conditions and immunotherapies.[12] The TACT trial revealed cardiovascular benefits of chelation therapy for removing accumulated metals in post-MI patients.[13]

These findings enable disease subtyping, such as lead-driven hypertension, pesticide-linked Parkinson's, and air pollution-associated dementia, opening the door to precision environmental medicine. Rather than treating all Parkinson's patients identically, clinicians could identify those with mitochondrial dysfunction from rotenone-class pesticide exposure and target interventions accordingly.[14]

The infrastructure for this precision approach is emerging. Epigenetic clocks can now measure biological aging acceleration from cumulative exposures.[15] High-throughput proteomics platforms detect organ-specific damage signatures.[16] Combining exposure biomarkers with disease subtyping creates a framework for matching the right intervention to the right patient. This is the same stratified medicine revolution that transformed oncology, now applied to exposure-driven disease.

1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. PubMed
2. Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252–260. PubMed
3. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:484–493. PubMed
4. Global Wellness Institute. Global Wellness Economy Monitor 2023. Miami, FL: GWI, 2023.
5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. PubMed
6. Dorsey ER, et al. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8:S3–S8. PubMed
7. Tanner CM, et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011;119:866–872. PubMed
8. Peters R, et al. Air pollution and dementia: a systematic review. J Alzheimers Dis. 2019;70:S145–S163. PubMed
9. Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016;167:1469–1480. PubMed
10. Athauda D, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675. PubMed
11. Silverberg JI, et al. Tapinarof cream 1% once daily: Advances in atopic dermatitis. J Am Acad Dermatol. 2024;90:167–176. PubMed
12. Safe S, et al. Aryl hydrocarbon receptor (AhR) ligands as selective AhR modulators (SAhRMs). Int J Mol Sci. 2020;21:6654. PubMed
13. Lamas GA, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. JAMA. 2013;309:1241–1250. PubMed
14. Sherer TB, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003;23:10756–10764. PubMed
15. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19:371–384. PubMed
16. Gold L, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5:e15004. PubMed